Abstract: Two novel series of N-sulfonylamidino pyrimidine derivatives were synthesized via Cu-catalyzed three-component reaction of propargylated nucleobases with different benzenesulfonyl azides and amines. In this way 4-acetamido, 4-methyl and 4-carboxybenzenesulfonyl amidine products 15-26 in the uracil series and 4-acetamidobenzenesulfonyl amidine derivatives 27-29 in the cytosine series were prepared in 34−69 % yields. Attempts to prepare N-sulfonylamidino cytosine derivatives in reaction with 4-methylbenzenesulfonyl azide were unsuccessful. The cytosine derivatives 32 and 33 were prepared from the N-sulfonylamidino uracil derivatives via the C4 triazole intermediates. The prepared N-sulfonylamidino pyrimidine derivatives 1-28 were tested for the antiproliferative activity on a panel of seven tumor cell lines of different histological origin (HeLa, Caco-2, NCI-H358, Raji, HuT78, K562, Jurkat) and on normal MDCK I cells. Most of the synthesized compounds showed antiproliferative activity on the tested cell lines.
INTRODUCTION
N the last two decades, our group has been intensively involved in the design and synthesis of a new series of N-sulfonyl nucleobase derivatives that exhibit antitumor activity. [1] [2] [3] [4] We have shown that N-1-sulfonylpyrimidine derivatives have strong antiproliferative activity on human tumor cell lines and an ability to induce apoptosis in the treated tumor cells. [5] [6] [7] [8] [9] [10] In vivo experiments showed that some N-sulfonylcytosine derivatives had strong antitumor activity against mouse mammary carcinoma. [9, [11] [12] [13] [14] Recently, we reported an efficient multicomponent synthesis of the new N-sulfonylamidino thymine derivatives 1−14 using Cu(I) catalyzed three component reactions of 1-propargyl thymine, selected benzenesulfonyl azides, and amines or ammonium salts (Table 1) . [15] We have shown that this one-pot three component reaction appears to be advantageous for the preparation of variously substituted N-sulfonylamidino thymine derivatives in moderate to good yields and opens the way for the preparation of the libraries of other nucleobase N-sulfonylamidino derivatives as possible biologically active molecules.
As the next step in our research, we report here on the synthesis of novel N-sulfonylamidine derivatives in uracil and cytosine series and the results of in vitro activity of N-sulfonylamidine-derived pyrimidine analogues on the growth of different tumor cell lines.
I General Procedures for the Preparation
of N-Sulfonyl Amidines (Table 1) METHOD A To a stirred mixture of alkyne (1 mmol), sulfonyl azide (1.2 mmol) and CuI (0.1 mmol) in dry THF (2 mL) amine nucleophile (1.2 mmol) was slowly added. The reaction mixture was stirred for 24 h at room temperature and diluted with a small amount of cold methanol. The product was collected by filtration and dissolved in hot MeOH. The crude amidine product was filtered through a short Al2O3 column, evaporated and the analytically pure product was obtained by recrystallization using methanol.
METHOD B
To a stirred mixture of alkyne (1 mmol), CuI (0.1 mmol) and amine / ammonium salt (1 mmol) in dry CH2Cl2 (2−5 mL) triethylamine (1.5 mmol) was slowly added and the color of the suspension turned to a light yellow. After that, sulfonyl azide (1 mmol) was added. The reaction mixture was stirred for 24 h at room temperature and diluted with a small amount of cold methanol. The product was collected by filtration and dissolved in hot MeOH. The crude amidine product was filtered through a short Al2O3 column, evaporated and the analytically pure product was obtained by recrystallization using methanol.
METHOD C
To a stirred mixture of alkyne (1 mmol), sulfonyl azide (1.2 mmol) and CuI (0.1 mmol) in THF (2 mL) cooled to 0 °C, amine nucleophile (2 mmol) was slowly added. The reaction mixture was stirred for 24 h (4 h in the case of compound 25) at room temperature, dissolved in MeOH and filtered through a short Celite column. The filtrate was partially evaporated and the residue was filtered off. The crude product was dissolved in 5 % aq. NaHCO3 and the water solution was washed with dichloromethane and ethyl acetate. The water phase was neutralized with 5 % CH3COOH and partially evaporated. The product was collected by filtration and recrystallized from methanol. ; 1 H NMR (600 MHz, DMSO-d6) δ / ppm: 11.32 (brs, 1H, NH-3'), 10.22 (s, 1H, NH-Ac), 7.72 (s, 4H, Ar), 7.45 (d,1H, J6',5' = 7.8 Hz, H-6'), 5.63 (d, 1H, J5',6' = 7.8 Hz, H-5'), 4.27 (m, 1H, CH-(CH3)2), 3.95 (t, 2H, J3,2 = 7.4 Hz, CH2-3), 3.65 (m, 1H, CH-(CH3)2), 3.20 (t, 2H, J2,3 = 7.4 Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 1.20 (pt, 12H, J = 6.5 Hz, CH-(CH3)2); 13 C NMR (150 MHz, DMSO-d6) δ / ppm: 168.8 (s, CO-CH3), 163.7 (s, C-4'), 161.6 (s, C-1), 151.0 (s, C-2'), 145.0 (d, C-6'), 141.9 (s, Ar), 138.1 (s, Ar), 126.5 (d, Ar), 118.3 (d, Ar), 101.6 (d, C-5'), 50.2 (d, CH-(CH3)2), 47.3 (d, CH-(CH3)2), 45.3 (t, CH2-3), 31.3 (t, CH2-2), 24.0 (q, CO-CH3), 20.1 (q, CH-(CH3)2), 19.6 (q, CH-(CH3)2). Anal. Calcd. mass fractions of elements, w / %, for C21H29N5O5S x 0.5H2O (Mr = 472.56) are: C, 53.37; H, 6.40; N, 14.82; S, 6.78; found: C, 53.59; H, 6.47; N, 15.06; S, 6.54 . ; 1 H NMR (300 MHz, DMSO-d6) δ / ppm: 11.34 (brs, 1H, NH-3'), 10.24 (s, 1H, NHAc), 7.75 (d, 2H, J = 8.9 Hz, Ar), 7.70 (d, 2H, J = 8.9 Hz, Ar), 7.43 (d, 1H, J6', 5' = 7.9 Hz, 5.62 (d, 1H, J5', 6' = 7.9 Hz, H-5'), 3.97 (t, 2H, J3,2 = 7.3 CH2-3), 3.49 (q, 2H, J = 6.9 CH2-CH3), 3.38 (q, 2H, J = 6.9 CH2-CH3), 3.15 (t, 2H, J2,3 = 7.3 Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 1.16 (t, 3H, J = 7.8 Hz, CH2-CH3), 1.01 (t, 3H, J = 7.8 Hz, CH2-CH3), 13 C NMR (150 MHz, DMSOd6) δ / ppm: 168.9 (s, CO-CH3), 163.7 (s, C-4'), 162.9 (s, C-1), 151.0 (s, C-2'), 144.9 (d, C-6'), 142.0 (s, Ar), 138.1 (s, Ar), 126.6 (d, Ar), 118.4 (d, Ar), 101.7 (d, , 45.4 (t, CH2-3), 43.2 (t, CH2-CH3), 43.0 (t, CH2-CH3), 29.9 (t, CH2-2), 24.1 (q, CO-CH3), 13.9 (q, CH2-CH3), 11.8 (q, CH2-CH3). Anal. Calcd. mass fractions of elements, w / %, for C19H25N5O5S (Mr = 435.49) are: C, 52.40; H, 5.78; N, 16.08; S, 7.36; found: C, 52.16; H, 5.76; N, 16.30; S, 7.07 . ',5' = 7.8 Hz, H-6'), 5.55 (d, 1H, J5',6' = 7.8 Hz, H-5'), 4.02 (t, 2H, J3,2 = 6.1 Hz, CH2-3), 3.86 (m, 1H, CH-(CH3)2), 2.89 (t, 2H, J2,3 = 6.1 Hz, CH2-2), 2.07 (s, 3H, CO-CH3), 1.01 (d, 6H, J = 6.5 Hz, CH-(CH3)2), 13 C NMR (150 MHz, DMSO-d6) δ / ppm: 169.3 (s, CO-CH3), 164.3 (s, C-4'), 163.6 (s, C-1), 151.2 (s, C-2'), 145.7 (d, C-6'), 142.0 (s, Ar), 138.6 (s, Ar), 127.1 (d, Ar), 118.8 (d, Ar), 101.5 (d, C-5'), 45.8 (t, CH2-3), 43.2 (d, CH-(CH3)2), 33.3 (t, CH2-2), 24.1 (q, CO-CH3), 21.1 (q, CH-(CH3)2). Anal. Calcd. mass fractions of elements, w / %, for C18H23N5O5S × 1.5H2O (Mr = 448.49) are: C, 48.20; H, 5.84; N, 15.62; S, 7.15; found: C, 48.29; H, 5.48; N, 15.76; S, 7.13 . 1H, 10.24 (s, 1H, 8.72 (brs, 1H, 7.74 (d, 2H, J = 8.9 Hz, Ar), 7.70 (d, 2H, J = 8.9 Hz, Ar), 7.37 (d, 1H, J6', 5' = 7.8 Hz, 5.55 (d, 1H, J5', 6' = 7.8 Hz, , 3.99 (t, 2H, J3,2 = 6.2 Hz, CH2-3), 3.98 (m, 1H, CH-cyclopentyl), 2.91 (t, 2H, J2,3 = 6.2 Hz, CH2-2), 2.07 (s, 3H, CH3-CO), 1.75 (m, 2H, CH2-cyclopentyl), 1.56 (m, 2H, CH2-cyclopentyl), 1.45 (m, 2H, CH2-cyclopentyl), 1.38 (m, 2H, CH2-cyclopentyl); 13 C NMR (150 MHz, DMSO-d6) δ / ppm: 168.8 (s, CO-CH3), 164.0 (s, C-4'), 163.8 (s, C-1), 150.7 (s, C-2'), 145.2 (d, C-6') 141.9 (s, Ar), 138.1 (s, Ar), 126.6 (d, Ar), 118.3 (d, Ar), 101.0 (d, C-5'), 52.9 (d, CH-cyclopentyl), 45.7 (t, CH2-3), 33.1 (t, CH2-2), 31.4 (t, CH2-cyclopentyl), 24.1 (q, CO-CH3), 23.5 (t, CH2-cyclopentyl). Anal. Calcd. mass fractions of elements, w / %, for C20H25N5O5S x H2O (Mr = 465.52) are: C, 51.60; H, 5.84; N, 15.04; S, 6.88; found: C, 51.53; H, 5.71; N, 15.08; S, 6.77 . H, 4.72; N, 15.75; S, 6.01; found: C, 53.86; H, 4.69; N, 15.70; S, 6.30 . , 55.86; H, 4.48; N, 16.99; S, 6.48; found: C, 55.68; H, 4.38; N, 16.98; S, 6. ',5' = 7.8 Hz, H-6'), 5.28 (dd, 1H, J5',6' = 7.8 Hz, J5',NH-3' = 2.1 Hz, H-5'), 3.81 (t, 2H, J3,2 = 6.4 Hz, CH2-3), 2.57 (t, 2H, J2,3 = 6.4 Hz, CH2-2), 2.08 (s, 3H, CO-CH3). 13 C NMR (150 MHz, DMSO-d6) δ / ppm: 168.9 (s, CO-CH3), 165.8 (s, C-4'), 163.6 (s, C-1), 150.7 (s, C-2'), 145.6 (d, C-6'), 142.6 (s, Ar) 136.1 (s, Ar), 127.2 (d, Ar), 118.4 (d, Ar), 100.4 (d, C-5'), 45.2 (t, CH2-3), 34.8 (t, CH2-2), 24.1 (q, CO-CH3). Anal. Calcd. mass fractions of elements, w / %, for C15H17N5O5S (Mr = 373.39) are: C, 47.49; H, 4.52; N, 18.46; S, 8.45; found: C, 47.19; H, 4.51; N, 18.09; S, 8.37 . , 57.12; H, 6.71; N, 13.32; S, 7.62; found: C, 56.92; H, 6.79; N, 13.08; S, 7.74 . , 5.98; N, 13.85; S, 7.93; found: C, 56.15; H, 5.80; N, 13.47; S, 7.96 . , J5',6' = 7.8 Hz, H-5'), 4.04 (t, 2H, J3,2 = 6.1 Hz, CH2-3), 3.87 (m, 1H, CH-(CH3)2), 2.92 (t, 2H, J2,3 = 6.1 Hz, CH2-2), 1.01 (d, 6H, J = 6.6 Hz, CH-(CH3)2); 13 C-NMR (150 MHz, DMSO-d6) δ / ppm: 163.3 (s, C-4'), 163.2 (s, C-1), 154.6 (s, C-2'), 150.2 (s, Ar) 144.7 (d, C-6'), 140.2 (s, Ar), 128.8 (d, Ar), 124.6 (d, Ar), 100.5 (d, C-5'), 45.2 (t, CH2-3), 42.7 (d, CH-(CH3)2), 32.8 (t, CH2-2), 20.6 (q, CH-(CH3)2). Anal. Calcd. mass fractions of elements, w / %, for C17H20N4O6S × 1.5H2O (Mr = 435.45) are: C, 46.89; H, 5.32; N, 12.86; S, 7.36; found: C, 46.53; H, 5.20; N, 12.48; S, 7.19 . , 52.48; H, 6.71; N, 17.48; S, 6.67; found: C, 52.12; H, 6.39; N, 16.99; S, 6.56 . , 5.87; N, 18.82; S, 7.18; found: C, 50.75; H, 5.94; N, 18.65; S, 7.35 . 
N 1 -CYCLOPENTYL-N 2 -(4-METYLBENZENESULFONYL)-3-(4-(3-NITRO-1H-1,2,4-TRIAZOLE-1-YL)-2-OXO-3,4-DIHYDROPYRIMIDINE-1(2H)-YL)PROPIONAMIDINE (31)
To a stirred mixture of uracil derivative 18 (100 mg, 0.25 mmol) in pyridine (1 mL) under argon, 1-(mesitylsulfonyl)-3-nitro-1H-1,2,4-triazole) (MSNT) (265 mg, 1.14 mmol) and diphenylphosphate (30 mg, 0.12 mmol) were added. After stirring the reaction mixture for 48 hours at room temperature, the pyridine was evaporated and methanol (10 mL 48 .9 (t, CH2-3), 32.5 (t, CH2-2), 31.6 (t, CH2-cyclopentyl), 23.5 (t, CH2-cyclopentyl), 20.9 (q, CH3-Ts).
N 1 ,N 1 -DIISOPROPYL-N 2 -(4-METYLBENZENESULFONYL)-3-(4-AMINO-2-OXOPYRIMIDIN-2(1H)-YL)PROPANAMIDINE
(32) To a suspension of compound 30 (77.8 mg, 0.15 mmol) in dioxane (3 mL) ammonium hydroxide (6 mL) was added. After stirring the reaction mixture for 24 hours at room temperature the solvent was evaporated under reduced pressure. The residue was purified by preparative chromatography (CH2Cl2/MeOH 9:1) to give product 32 as a white powder: 62 mg (98 %): m.p. = 220−222 °C; Rf = 0.47 (CH2Cl2 / MeOH = 9 : 1); UV (MeOH): λmax / nm: 249 (log ε / dm -3 mol -1 cm -1 : 4. , 56.56; H, 6.25; N, 17.36; S, 7.95; found: C, 56.40; H, 6.40; N, 17.22; S, 7.53 .
Cell Culturing and MTT Test [16]
N-sulfonylamidino pyrimidine derivatives 1−28 were selected for preliminary in vitro cytotoxicity testing against normal Madine Darby canine kidney (MDCKI) cells, and seven tumor cell lines of different histological origin: cervix adenocarcinoma cells (HeLa), human epithelial colorectal adenocarcinoma cells (Caco-2), human caucasian bronchioalveolar carcinoma cells (NCI-H358), human DOI: 10.5562/cca3273 Croat. Chem. Acta 2017, 90(4), 625-636 Burkitt lymphoma cells (Raji), human T cell lymphoma cells (HuT78), chronic myelogenous leukemia cells (K562) and human acute T cell leukemia cells (Jurkat). The NCI-H358, Raji, HuT78, K562 and Jurkat cells were grown in RPMI 1640 medium (Gibco, EU) supplemented with 10 % heat-inactivated fetal bovine serum FBS (Gibco, EU), 2 × 10 -3 mol dm -3 glutamine (Gibco, EU), 1 × 10 -3 mol dm -3 sodium pyruvate (Gibco, EU), 1 × 10 -2 mol dm -3 HEPES (Sigma-Aldrich, USA) and 100 U/0.1 mg penicillin/streptomycin. The MDCKI, HeLa and Caco-2 cells were grown in Dulbecco's Modified Eagle Medium DMEM (Gibco, EU), supplemented with 10 % FBS, 2 × 10 -3 mol dm -3 glutamine and 100 U / 0.1 mg penicillin/streptomycin; in tissue culture flasks and grown as monolayers. To detach them from the flask surface, cells were trypsinized using a 0.25 % trypsin/EDTA solution. Cells were cultured in a humidified atmosphere under the conditions of 37 o C / 5 % of CO2 gas in a CO2 incubator (Shell Lab, Sheldon Manufacturing, USA).
Tested compounds were dissolved in dimethyl sulfoxide as a 1 × 10 -2 mol dm -3 stock solution. Working dilutions were prepared in high pure water at a concentration range 10 -4 -10 -7 mol dm -3 .
For the MTT test, the adherent cells, MDCK1, HeLa, and Caco-2, were seeded in 96 micro-well plates at concentration of 2 × 10 4 cells / cm 3 and allowed to attach overnight in the CO2 incubator. After 72 hours of the exposure to tested compounds, medium was replaced with 5 mg cm -3 MTT solution and the resulting formazane crystals were dissolved in DMSO.
Leukemia cells (1 × 10 5 cells ⁄ cm 3 ), were plated onto 96 micro-well plates and after 72 hours of incubation, 5 mg cm -3 MTT solution was added to each well and incubated 4 hours in the CO2 incubator. To each well, 10 % SDS with 0.01 mol dm -3 HCl was added to dissolve waterinsoluble MTT-formazane crystals. The microplate reader (iMark, BIO RAD, Hercules, CA, USA) was used for measurement of the absorbance at 595 nm. All experiments were performed three times in triplicates.
The GI50 value, defined as the concentration of compound achieving 50 % of cell growth inhibition was calculated and used to compare cytotoxicity among the compounds. Calculation of GI50 value curves and QC analysis is performed by using the Excel tools and GraphPadPrism software (La Jolla, CA), v. 5.03. Briefly, individual concentration effect curves are generated by plotting the logarithm of the concentration of tested compounds (X) vs. corresponding percent inhibition values (Y) using least squares fit. The best fit GI50 values are calculated using Log (inhibitor) versus normalized responseVariable slope equation, where Y = 100 / (1 + 10^((log GI50-X) * HillSlope)). QC criteria parameters (Z0, S:B, R2, HillSlope) were checked for every GI50 curve.
RESULTS AND DISCUSSION

Synthesis
Cu(I)-catalyzed 1,3-dipolar cycloadditions of azides with terminal alkynes (CuAAC) afford a 1,4-disubstituted 1,2,3 triazole. This powerful, widely used reaction [17, 18] is the most representative example of click chemistry. Employment of electron-deficient phosphoryl or sulfonyl azides led to a path change in the copper-catalyzed reaction with 1-alkynes. [19] Proposed key intermediate ketenimine, which is generated in situ upon ring-opening of the corresponding copper-triazole intermediate, undergoes addition reactions with various nucleophiles such as amines, alcohols, water or heterocycle compounds to give amidines, imidates, amides and other coupled compounds. [20] These three component reactions allow access to biologically interesting compounds that are typically otherwise prepared by multistep functional group transformations.
The synthesis of target N-sulfonylamidino uracils 15−26 was started by the preparation of 1-propargyl uracil. [21, 22] First, the uracil was silylated with N,Obis(trimethylsilyl)acetamide (BSA) in acetonitrile and then the silylated intermediate was treated with propargyl bromide, giving the N-1 alkylated product in 64 % yield.
The copper-catalyzed reactions of 1-propargyl uracil with three different commercially available sulfonyl azides (4-acetamidobenzenesulfonyl, 4-methylbenzenesulfonyl and 4-carboxybenzenesulfonyl) and amines or amine salts were performed in THF or dichloromethane at room temperature affording N-sulfonylamidino uracils 15−26 in the 34−69 % yields (Table 1 ). All reactions included 20 % molar excess of sulfonyl azide and amine, except the reaction with 4-carboxybenzenesulfonyl azide (entry 12-14), where a 100 % molar excess of amine was required. In the case of amine/ammonium salts (entry 10 and 11), additional triethylamine base in 50 % molar excess was used. [15] Table 1 provides a comparison between the previously reported [15] N-sulfonylamidino thymine derivatives 1−14 and newly synthesized compounds from the uracil series 15−26. Compared to the propargyl thymine, in all reactions, a slightly lower reactivity of propargyl uracil is apparent, with the exception of compound 24 (entry 12, Table 1 ). Among used azides, reaction with 4-acetamidobenzenesulfonyl azide afforded products with highest yields.
As expected reactions of 1-propargyl uracil with 4-acetamidobenzenesulfonyl azide or 4-methylbenzenesulfonyl azide (tosyl azide) and with secondary amines (Table 1 , compounds 15, 16 and 22) gave better yields compared to those with primary amines (Table 1, Table 1 . Three-component coupling reactions of 1-propargyl thymine and 1-propargyl uracil with various aromatic sulfonyl azides, amines, and ammonium salts. compounds 17, 18 and 23) and aromatic amine (Table 1 , compound 19). The reactions with 4-carboxybenzenesulfonyl azide afforded products 24-26 in lower yields (Table 1, entry 12-14) . A similar trend has been noticed for thymine series. A significant difference between the reactivity of propargyl uracil and propargyl thymine was observed since the preparations of the uracil analogs of compounds 10 and 11, failed. Although identical conditions were used, with the same reagents, there was no sign that the reaction occurred even at elevated temperatures, and the unreacted 1-propargyl uracil was isolated from the reaction mixture (> 90 %).
In the next step we decided to examine the conditions for the three-component coupling reactions with 1-propargyl cytosine, which was synthesized by the known condensation method of N 4 -acetylcytosine with propargyl bromide. [23] The cytosine amino group was acetylated with acetic anhydride in pyridine [24] and obtained N 4 -acetylcytosine was activated with K2CO3 in DMF and condensed with propargyl bromide. In the reaction mixture N1 and O2 regioisomers were obtained in the 96:4 ratio. N1 isomer was isolated by recrystallization from water and the acetyl group was readily removed by methanolic ammonia to give the desired N-1-propargyl cytosine.
Next, using the same conditions for Cu-catalyzed three-component reaction (Method A), 1-propargyl cytosine was reacted with 4-acetamidobenzenesulfonyl azide and secondary or primary amines giving desired products 27-29 in 45-62 % yields (Scheme 1). Cu-catalyzed three-component reactions of 1-propargyl cytosine and ammonium chloride (Method B) or 4-methylbenzenesulfonyl azide (Method A) failed to give any N-sulfonylamidine product and the starting material, 1-propargyl cytosine, was completely recovered.
Then we decided to solve this problem by known transformations of uracil into cytosine derivatives. [25] [26] [27] [28] In these methods, the C4 carbonyl group of the uracil derivative is converted to a leaving group (chlorine, 1,2,4-triazole, etc.) which undergoes nucleophilic substitution with ammonia providing the corresponding cytosine derivative. The most successful method was with 1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT). [27] The N-sulfonylamidino uracil derivatives 15 and 18 were treated with MSNT in the presence of diphenyl phosphate giving pyrimidine intermediates 30 and 31 in 86 % and 56 % yield, respectively. The latter compounds in the reaction with ammonium hydroxide in dioxane afforded desired N-sulfonylamidino cytosine derivatives 32 and 33 in 98 % and 66 % yield, respectively (Scheme 2).
In vitro Antiproliferative Screening
We have shown before that N-1-sulfonylpyrimidine derivatives have strong and selective antiproliferative activity on different human tumor cell lines in vitro and on xenograft model in vivo. [5] [6] [7] [8] [9] [10] Amidines are important units in chemistry for the synthesis of heterocycles [29, 30] and widely used in bioactive chemicals and drug molecular design. [31] [32] [33] We assumed the improved antiproliferative capacity of novel hybrid compounds could be obtained if Table 2 . Inhibitory effects of N-sulfonylamidine pyrimidine derivatives on the growth of normal and human tumor cells.
GI50 (x 10 -6 mol dm -3 ) (a) Comp.
Normal cells
Solid 11.0 ± 3.4 9.8 ± 1.7 11.0 ± 4.6 16.4 ± 3.8 13.9 ± 3.5 15.7 ± 2.8 > 100 39.2 ± 2.5 7 > 100 > 100 > 100 > 100 > 100 > 100 > 100 61.9 ± 40.1 8 10.4 ± 4.6 8.6 ± 0.5 12.2 ± 2.9 15.4 ± 1.3 13.6 ± 4.0 15.7 ± 2.8 > 100 38.2 ± 3.2 9 9.0 ± 0.7 9.1 ± 2.0 10.8 ± 4.8 15.7 ± 3.6 12.8 ± 3.8 14.8 ± 0.6 > 100 38.0 ± 2.8 10 8.0 ± 0.4 7.9 ± 0.9 9.6 ± 0.3 17.3 ± 5.7 12.6 ± 2.7 13.8 ± 3.2 > 100 37.6 ± 2.1 11 > 100 52.9 ± 8.2 > 100 15.8 ± 3.1 69.9 ± 4.1 79.4 ± 26.0 > 100 38.3 ± 3.8 12 9.8 ± 5.6 7.7 ±1.3 11.3 ± 7.2 > 100 72.1 ± 0 2.4 ± 0 7.1 ± 0 4.1 ± 0 13 > 100 > 100 > 100 > 100 > 100 > 100 > 100 69.3 ± 0 14 > 100 > 100 > 100 > 100 89.7 ± 0 62.1 ± 0 21.9 ± 0 27.8 ± 0 15 > 100 > 100 > 100 > 100 85.4 ± 0 84.6 ± 4.1 > 100 57.5 ± 2.6 16 9.0 ± 1. (a) GI50 -Compound concentration that inhibited cell growth by 50 %. Exponentially growing cells were treated with compounds during 72-h period. Cytotoxicity was analyzed using MTT survival assay.
the hybrids contain an amidine unit, a sulfonyl group, and a pyrimidine nucleobase in the same structure. In this study, N-sulfonylamidino pyrimidine derivatives 1−28 were selected for preliminary in vitro cytotoxicity testing against normal MDCKI cells, carcinoma cells (HeLa, Caco-2, NCI-H358), two lymphoma cells (Raji, HuT78), leukemia cells (K562, Jurkat) and in a parallel with 5-fluorouracil (5-FU) as a standard antitumor drug (Table  2 ). All cells were treated by investigated compounds in the range of concentration 10 -7 -10 -4 mol dm -3 .
As indicated in Table 2 , two large groups of prepared N-sulfonylamidine-derived pyrimidine analogues showed great variation in the antiproliferative effect on tumor cell lines, depending on the cell line and structure of the tested compounds.
The first group of N-sulfonylamidino derivatives of thymine (2, 6, 8, 9, 10), uracil (16, 20, 22, 23) and cytosine (27, 28), which share the same or similar chemical characteristics and functional groups, shows strong antiproliferative effects on all treated cell lines. The GI50 ranged from 8 to 41 × 10 -6 mol dm -3 for MDCK I, HeLa, Caco-2, NCI-H358, Raji, K562 and Jurkat cells, with exception of HuT78 cells where antiproliferative activity of tested compounds in applied highest concentration of 1 × 10 -4 mol dm -3 was not observed.
The most prominent difference in the antitumor activity between thymine and uracil series was obtained between compounds 12 and 24, having the same N1 substituent. The GI50 of normal MDCKI, tumor Caco-2, HeLa, HuT78, K562, and Jurkat cells induced by N-sulfonylamidino thymine 12 was between 2.4 × 10 -6 and 11.3 × 10 -6 mol dm -3 , whereas, as in the first group of tested compounds, antiproliferative activity on HuT78 cells in applied highest concentration of 10 -4 mol dm -3 was not noticed. On the other hand, N-sulfonylamidino uracil 24 exhibits antiproliferative activity against lymphoma (HuT78 GI50 = 24.9 × 10 -6 mol dm -3 ) and leukemia (K562: GI50 = 48.7 × 10 -6 mol dm -3 ; Jurkat GI50 = 38.2 × 10 -6 mol dm -3 ) cell lines, while on normal (MDCK I) and tumor (HeLa, Caco2, NCI-H358, Raji) cell lines cytotoxic effects were not observed.
Compared to the first group of compounds, the second group of N-sulfonylamidino thymine (1, 3-5, 7, 13) and uracil (15, 17-19, 21, 25) derivatives, carrying the same N1 substituent, were mainly deprived of any inhibitory activities against the normal, solid tumor cell lines, leukemia and K562 lymphoma cell lines. Except compound 5 (GI50 = 44.8 × 10 -6 mol dm -3 ), all of them showed very weak antiproliferative capacity on the Jurkat cells (GI50 ∼ 60-100 × 10 -6 mol dm -3 ).
In addition, N-sulfonylamidino thymine 14 displayed good cytostatic activities on Raji and Jurkat cell lines, with GI50 values 21.9 × 10 -6 mol dm -3 and 27.8 × 10 -6 mol dm -3 , respectively, while its structural analogue with uracil (26) shows strong antiproliferative effect on Raji cells (GI50 = 16.0 × 10 -6 mol dm -3 ).
CONCLUSIONS
In conclusion, the series of new aliphatic N-sulfonylamidino pyrimidine derivatives incorporating nucleobase, Nsulfonyl and amidine pharmacophores in the structure were synthesized by Cu(I)-catalyzed three-component coupling of 1-propargyl nucleobase, benzenesulfonyl azides and amines. New N-sulfonylamidino pyrimidine derivatives possess good inhibitory potential against tested tumor cells. These results stimulate further studies directed to investigate their mechanisms of action.
